0RAG.L - ABIONYX Pharma SA
| Previous close | 1.2660 |
| Open | 1.2660 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.2340 - 1.2660 |
| 52-week range | 1.2340 - 2.3600 |
| Volume | |
| Avg. volume | 1,751 |
| Market cap | 272,082 |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1480 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireABIONYX Pharma: Monthly statement of total voting rights and shares forming the company’s share capital
PARIS, June 07, 2023--Regulatory News: ABIONYX Pharma (Paris:ABNX):
Business WireABIONYX Pharma Provides Further Details on the Setting up of Its Equity-Linked Financing Facility
TOULOUSE, France & LAKELAND, Mich., May 29, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, clarifies fundamental points about the setting up of its latest equity-linked financing facility, after receiving questions from its shareholders and the financial community over the past few days.
Business WireABIONYX Pharma Accelerates Its Development by Launching a New Biomanufacturing Campaign Based on the Recently Announced Robust Innovative Process Supported by an Equity-linked Financing Facility
TOULOUSE, France & LAKELAND, Mich., May 23, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only human recombinant ApoA-I, announces the acceleration of its development by launching a new bioproduction campaign according to the new innovative robust process through the setting up of an equity-linked financing facility.
Business WireABIONYX Pharma Provides an Update on Its Activity and Its Cash Position for the First Quarter 2023
TOULOUSE, France & LAKELAND, Mich., May 17, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, today provides an update on its activity and cash position as of March 31, 2023.
Business WireABIONYX Pharma Announces the Successful Manufacturing of the First Batch of CER-001 With Recombinant Human ApoA-I Using a New Innovative and Robust Industrial Bioprocess
TOULOUSE, France & LAKELAND, Mich., May 10, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, announced the successful GMP (Good Manufacturing Practices) industrial biomanufacturing of a batch of CER-001 using an innovative and robust method.
Business WireABIONYX Pharma: Availability of the Universal Registration Document for the year 2022
TOULOUSE, France & LAKELAND, Mich., May 02, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces that it has filed with the "Autorité des Marchés Financiers" (AMF) its Universal Registration Document for the year ended December 31, 2022, dated April 28, 2023.
Business WireABIONYX Pharma Announces Its Strategy in Ophthalmology and New Positive Preclinical Results for the Deployment of Two Innovative Technology Platforms: Apotherapy and Biovectorization
TOULOUSE, France & LAKELAND, Mich., March 31, 2023--ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announced today announced its strategy in ophthalmology and new positive preclinical results in two innovative technological platforms: apotherapy and biovectorisation.
Business WireABIONYX Pharma Announces Its 2022 Full-year Financial Results
TOULOUSE, France & LAKELAND, Mich., March 29, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announced its 2022 financial annual results as approved by the full Board of Directors and an update on the activity to date. The audit procedures on the consolidated accounts have been completed. The certification report will be issued aft
Business WireABIONYX Pharma Provides an Update on Its Activity and Its Cash Position for the 4th Quarter 2022
TOULOUSE, France & LAKELAND, Mich., February 28, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today provides an update on its activity and cash position as of December 31, 2022.
Business WireABIONYX Pharma: Press Release
TOULOUSE, France & LAKELAND, Mich., February 03, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announced today that it has been informed by TVM Capital of the total sale of their shares on the market due to the liquidation of their funds that have reached maturity.
Business WireABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
TOULOUSE, France & LAKELAND, Mich., January 16, 2023--ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the pilot Phase 2a clinical trial evaluating CER-001, the only natural recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI) met its primary objective. There are no approved treatments for septic patie
Business WireABIONYX Pharma Announces Its Financial Agenda for the Year 2023
TOULOUSE, France & LAKELAND, Mich., January 13, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2023.
Business WireABIONYX Pharma Announces Its Cash Position and Provides an Activity Update on the 3rd quarter 2022
TOULOUSE, France & LAKELAND, Mich., November 17, 2022--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX –PEA PME eligible) (Paris:ABNX), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announces its cash position for the third quarter ended September 30, 2022 and reviews the highlights of the period.
Business WireABIONYX Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury
TOULOUSE, France & LAKELAND, Mich., October 04, 2022--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announces that the last patient has been enrolled in the Phase 2a clinical trial evaluating CER-001, Bio-HDL, as a potential treatment for patients with sepsis at high risk of developing acute kidney injury.
Business WireABIONYX Pharma Announces Its 2022 Half-Year Financial Results
TOULOUSE, France & LAKELAND, Mich., September 29, 2022--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announced its financial results for the first half of 2022.
Business WireABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Half Of 2022
TOULOUSE, France & LAKELAND, Mich., August 18, 2022--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today published its cash position for the 1st semester ended June 30, 2022 and reviewed the highlights of the period.
Business WireABIONYX Pharma Announces the Reinitiation of Coverage of Its Stock by TPICAP Midcap
TOULOUSE, France & LAKELAND, Mich., July 04, 2022--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces the reinitiation of coverage of its stock by TPICAP Midcap with a study entitled "Scaling Up", giving a buy recommendation with a target price of €8.10 per share.
Business WireABIONYX Pharma: Combined General Meeting of June 28, 2022
TOULOUSE, France & LAKELAND, Mich., June 30, 2022--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces that all resolutions were voted in accordance with the recommendations of the Board of Directors.